High Point Advisor Group LLC Alnylam Pharmaceuticals, Inc. Transaction History
High Point Advisor Group LLC
- $2.05 Billion
- Q3 2025
A detailed history of High Point Advisor Group LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, High Point Advisor Group LLC holds 704 shares of ALNY stock, worth $310,956. This represents 0.02% of its overall portfolio holdings.
Number of Shares
704Holding current value
$310,956% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
840Shares Held
118MCall Options Held
608KPut Options Held
678K-
Capital World Investors Los Angeles, CA16.8MShares$7.42 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.6MShares$5.99 Billion0.1% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.22 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.18 Billion0.49% of portfolio
-
Jpmorgan Chase & CO New York, NY4.54MShares$2.01 Billion0.14% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $54.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...